Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [4072]

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and...

Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA ( Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA )

Real-world cardiovascular risks with novel hormonal therapies in advanced...

Dr Dalia Kaakour - University of California, Irvine, USA

Real-world cardiovascular risks with novel hormonal therapies in advanced prostate cancer ( Dr Dalia Kaakour - University of California, Irvine, USA )

Circulating tumour DNA shows high accuracy for monitoring testicular cancer...

Dr Dalia Kaakour - University of California, Irvine, USA

Circulating tumour DNA shows high accuracy for monitoring testicular cancer across all stages ( Dr Dalia Kaakour - University of California, Irvine, USA )

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis...

Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer ( Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA )

Belzutifan plus palbociclib shows modest activity with manageable safety in...

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced...

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Circulating tumour DNA dynamics predict outcomes with pembrolizumab in advanced kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

HIF-2α inhibitor Cas shows durable responses and biomarker-linked benefit in metastatic kidney cancer ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Pembrolizumab plus belzutifan improves disease-free survival in high-risk...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Darolutamide improves progression-free survival across comorbidities in...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Darolutamide improves progression-free survival across comorbidities in metastatic hormone-sensitive prostate cancer ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high...

Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The...

Induction ipilimumab plus nivolumab followed by chemoradiotherapy achieves high bladder preservation and survival in MIBC ( Dr Jan-Jaap Mellema - The Netherlands Cancer Institute, Amsterdam, The Netherlands )

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL...

Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA

Lutetium-177 PSMA-617 improves progression-free survival without worsening QoL in mHSPC ( Dr Michael Morris - Memorial Sloan Kettering Cancer Center, New York, USA )

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment...

Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension ( Dr Neal Shore - Carolina Urologic Research Center, Myrtle Beach, USA )

More from ecancer